Scan how global healthcare investors are repositioning around Nippon Shinyaku’s index exit by reviewing our curated list of list of solid balance sheet and fundamentals (22 results).
Nippon Shinyaku’s story still comes back to whether you believe its mix of specialty pharmaceuticals and functional foods can keep earning its way through a tougher patch. Revenue and net income both declined in the latest year, and analysts currently expect earnings and sales to fall over the next three years, which puts more pressure on execution around existing products and the late stage pipeline. The FTSE All World removal mainly affects who holds the stock, rather than what the laboratories and sales teams deliver day to day.
The near term debate is about earnings resilience and capital allocation. A P/E of 7.5x, lower than both the Japan market and domestic pharma peers, plus a 3.53% dividend and historically high quality earnings, gives the equity story a value and income tilt. Weak recent share performance, including a year to date decline of 36.6%, suggests confidence is already fragile, so any stumble on pricing, R&D productivity or the new management team’s decisions since their relatively recent arrival could matter more after the index exit.
Yet there is one structural issue around future profitability that deserves a closer look before getting too comfortable with that value tag...
There's only one way to know the right time to buy, sell or hold Nippon Shinyaku. Head to Simply Wall St's company report for the latest analysis of Nippon Shinyaku's Fair Value.
Do not just follow the ticker; dig into the data and build a conviction that is truly your own.
If you want to cross check Nippon Shinyaku against other opportunities, it helps to scan a wider field of companies with clear financial traits rather than start from scratch each time.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com